<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01656148</url>
  </required_header>
  <id_info>
    <org_study_id>FAME</org_study_id>
    <secondary_id>2011-006151-10</secondary_id>
    <nct_id>NCT01656148</nct_id>
  </id_info>
  <brief_title>FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra</brief_title>
  <acronym>FAME</acronym>
  <official_title>Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fampridine-SR is registered for the treatment of walking incapacity in MS patients. Two
      pivotal trials show that app. 40% of MS patients with walking incapacity can improve walking
      speed averagely 25% when recieving the drug. This has been shown using the Timed 25 Foot Walk
      Test (T25FW). No effect on cognition and upper limb function has been shown, but this has not
      been investigated in patients responding to the drug measured by the abovementioned test.

      The question is if this will be the case and also if another walking test, termed the Six
      Spot Step Test (SSST), will be more sensitive to the effect of Fampridine-SR.

      Primary outcome measure is the effect measured by SSST. The hypothesis is that SSST is not
      less sensitive to the effect of Fampridine-SR than T25FW.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean change in SSST</measure>
    <time_frame>SSST is measured before and at the end of four weeks of treatment</time_frame>
    <description>SSST is measured before treatment with Fampridine-SR. Then again measured at day 26, 27 or 28 of four weeks of treatment with Fampridine-SR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in T25FW</measure>
    <time_frame>Four weeks</time_frame>
    <description>T25FW is measured before four weeks of treatment with Fampridine-SR and then on day 26, 27 or 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in hip flexion, knee flexion and knee extension force</measure>
    <time_frame>Four weeks</time_frame>
    <description>Force in the abovementioned areas is measured by dynamometry before four weeks of treatment with Fampridine-SR and on day 26, 27 or 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change on Chair Rise Test</measure>
    <time_frame>Four weeks</time_frame>
    <description>Time to rise from a chair five times is measured before four weeks of treatment with Fampridine-SR and on day 26, 27 or 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change on 9-Hole Peg Test (9HPT)</measure>
    <time_frame>Four weeks</time_frame>
    <description>9HPT is measured before four weeks of treatment with Fampridine-SR and on day 26, 27 or 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change on Symbol Digit Modalitites Test (SDMT)</measure>
    <time_frame>Four weeks</time_frame>
    <description>SDMT is measured before four weeks of treatment with Fampridine-SR and on day 26, 27 or 28.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fampridine-SR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initially all participants receive Fampridine-SR 10 mg BID in an open label enrichment phase lasting four weeks. Those 40% responding the most by SSST will go onto phase two. 50% of these will receive 10 mg Fampridine-SR BID for four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the intervention phase 50% will receive placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fampridine-SR</intervention_name>
    <description>Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.</description>
    <arm_group_label>Fampridine-SR</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Fampyra (Ampyra in the US).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinically definite multiple sclerosis diagnosed according to the
             McDonald criteria

          -  EDSS 4-7

          -  Pyramidal FS &gt;= 2

        Exclusion Criteria:

          -  History of epileptic seizures

          -  MS relapse or change in disease modifying treatment (DMT) within 60 days

          -  cancer within five years

          -  uncontrolled hypertension

          -  clinically important cardiac, hepatic, renal or pulmonary disease

          -  pregnancy

          -  breast feeding

          -  concomitant treatment with cimetidine, carvedilol, propranolol and metformin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik B Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Regional Health Services Research, University of Southern Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Esbjerg Hospital</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sønderborg Hospital</name>
      <address>
        <city>Sønderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev. 2002;(4):CD001330. Review.</citation>
    <PMID>12804404</PMID>
  </reference>
  <reference>
    <citation>Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9. Review.</citation>
    <PMID>16472864</PMID>
  </reference>
  <reference>
    <citation>Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology. 1997 Apr;48(4):817-21.</citation>
    <PMID>9109861</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, Marinucci L, Blight AR. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler. 2007 Apr;13(3):357-68. Epub 2007 Jan 29.</citation>
    <PMID>17439905</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 Feb 28;373(9665):732-8. doi: 10.1016/S0140-6736(09)60442-6.</citation>
    <PMID>19249634</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F202 Study Group. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008 Oct 7;71(15):1134-41. doi: 10.1212/01.wnl.0000326213.89576.0e. Epub 2008 Jul 30.</citation>
    <PMID>18672472</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010 Oct;68(4):494-502. doi: 10.1002/ana.22240.</citation>
    <PMID>20976768</PMID>
  </reference>
  <reference>
    <citation>Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999 May;122 ( Pt 5):871-82.</citation>
    <PMID>10355672</PMID>
  </reference>
  <reference>
    <citation>Nieuwenhuis MM, Van Tongeren H, Sørensen PS, Ravnborg M. The six spot step test: a new measurement for walking ability in multiple sclerosis. Mult Scler. 2006 Aug;12(4):495-500.</citation>
    <PMID>16900764</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2012</study_first_submitted>
  <study_first_submitted_qc>July 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Henrik Boye Jensen</investigator_full_name>
    <investigator_title>MD, PhD Fellow</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Walking disablility</keyword>
  <keyword>Mobility</keyword>
  <keyword>Six Spot Step Test</keyword>
  <keyword>Outcome measures</keyword>
  <keyword>Fampridine-SR</keyword>
  <keyword>Fampyra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

